

News

Lugano, December 20th, 2019

CERBIOS-PHARMA SUCCESSFULLY PASSES SWISSMEDIC INSPECTION OF ITS INNOVATIVE ADCS CONJUGATION SUITE

Cerbios is proud to announce successful SwissMedic authorization of its new cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs).



"The suite further expands Cerbios' ADCs capacities and consolidates Cerbios commitment to provide best-in-class bioconjugation services for its partners worldwide" says Matteo Piazza Cerbios- Pharma BD Manager.

The new and state-of-the-art facility, which uses both single use and dedicated equipments, is designed to maximize flexibility in order to accommodate novel bioconjugation approaches.

The future-proof facility is fully equipped with complete downstream capabilities (including single use chromatography) and will embed new manufacturing solutions to bypass common ADCs manufacturing limitations.

"Cerbios-Pharma is strategically positioning itself as a CDMO supplier offering a complete service for ADCs. For this reason, this investment and the authorization from Swiss Medic are key steps for us and allow us to continue supporting our customers for the development and manufacturing of their innovative ADCs" states Denis Angioletti, Chief Commercial Officer.

It also confirms the commitment of Cerbios-Pharma to continuous improvements and high standard of quality and service.

www.cerbios.swiss

Phone: +41 (0) 91 985 63 11

: +41 (0) 91 985 63 25



About Cerbios-Pharma SA

Cerbios is a private company with its headquarters in Lugano, Switzerland, specialized in developing and producing active pharmaceutical ingredients (APIs), both chemical and biological, for its clients around the world. Cerbios is a world leader for some generic products used primarily to treat respiratory, dermatological and oncological diseases.

Cerbios also offers its clients an exclusive service to develop and produce highly active pharmaceutical ingredients (HAPIs) and biological monoclonal antibody tablets, recombinant proteins, conjugated monoclonal antibodies (ADCs) and probiotics for pharmaceutical use.

Cerbios is capable of offering a complete service to develop and register pharmaceutical products, tablets supplied for clinical research phases, the necessary regulatory documentation and subsequent marketing supplies. Cerbios products are marketed around the entire world, primarily in the USA, Japan and Europe.

For more information please contact:

Cerbios-Pharma SA

Phone : +41 (0) 91 985 63 11 Fax : +41 (0) 91 985 63 25 Email : sales@cerbios.ch

Or use our online contact form.

Phone: +41 (0) 91 985 63 11

: +41 (0) 91 985 63 25